De-risk antibody selection with enhanced validation

At Abcam, we understand the importance of selecting an antibody that is specific and sensitive to your intended target. That's why we introduced our enhanced validation program to go above and beyond our already rigorous standard validation. Our antibodies are profiled through extensive specificity and sensitivity testing on up to 800 individual relevant disease cases, ensuring that our antibodies deliver reliable and precise results. By providing a broad range of carefully selected representative images, we offer you a detailed view of antibody performance in various disease settings, empowering you to make informed decisions with confidence.
As part of our enhanced validation program, we develop bespoke specificity assays like chromogenic multiplexing, peptide blocking assays, and analysis of target expression in modulated cell lines (knockout/over-expressing). These tailored assays ensure that our antibodies meet your unique research needs, delivering unparalleled specificity and sensitivity.
We also provide you with comprehensive validation data specific to both the target and its relevant research and clinical settings. With a combination of manual pathology scoring and AI-driven precision tissue analysis software, our pathology analysis methodology represents a blend of traditional expertise and cutting-edge technology. With Abcam, you can trust that you are using the most advanced, reliable, and thoroughly validated antibodies available, giving you the confidence to advance your research and clinical programs.
We’ve done the validation work so you don’t have to. Our dataset's broad range of representative images and thoroughly optimized protocols for IHC automated platforms like BOND RX and DISCOVERY ULTRA means you can proceed with confidence. Focus on the work that really matters and get precious time back from validation processes.
Product highlights
Anti-Claudin18.2 antibody [EPR19202]
- Bespoke isotype specificity data, (indirect ELISA, IHC peptide blocking)
- Validated in the most clinically relevant cancer cohorts (stomach, pancreas, colorectal and esphohagus)
- BPQC data available

Anti-TREM1 antibody [EPR22060-229]
- Chromogenic multiplex bespoke assay
- Validated in the most clinically relevant cancer cohorts (colon, lung and head and neck cancer)
- AI-driven digital image analysis
- Optimized protocols for Leica BONDTM RX and Roche Ventana DISCOVERY ULTRA

Anti-TROP2 antibody [EPR20043]
- KO cell line validated
- Validated in the most clinically relevant cancer cohorts (TNBC, breast, ovarian lung and endometrial cancer)
- AI-driven digital image analysis
- Optimized protocols for Leica BONDTM RX and Roche Ventana DISCOVERY ULTRA

Anti-Claudin 6 antibody [EPR28103-113]
- Bespoke specificity data
- AI-driven digital image analysis
- Optimized protocols for Leica BONDTM RX and Roche Ventana DISCOVERY ULTRA
